<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604682</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-001</org_study_id>
    <nct_id>NCT00604682</nct_id>
  </id_info>
  <brief_title>Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis</brief_title>
  <acronym>PSOR-001</acronym>
  <official_title>Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label study for patients with severe plaque type psoriasis. This study is looking to&#xD;
      evaluate the pharmacodynamic effect of CC10004 when taken for 29 days in reducing the&#xD;
      epidermal thickness in subjects with severe placque type psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2005</start_date>
  <completion_date type="Actual">December 1, 2005</completion_date>
  <primary_completion_date type="Actual">October 1, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the pharmacodynamic effect of orally administered CC10004 when taken for 29 days in reducing epidermal thickness in subjects with severe plaque-type psoriasis.</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of orally administered CC10004 in subjects with severe plaque-type psoriasis during the treatment and follow up phases.</measure>
    <time_frame>58 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the clinical efficacy of orally administered CC10004 when taken for 29 days in subjects with severe plaque-type psoriasis.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the clinical efficacy of CC10004 when taken for 29 days in subjects with psoriatic arthritis.</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Administration of CC10004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC10004</intervention_name>
    <description>2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted</description>
    <arm_group_label>Administration of CC10004</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Must understand and voluntarily sign an informed consent form&#xD;
&#xD;
          -  Must be age &gt; or = to 18 years to 65 years at the time of singing the informed consent&#xD;
             form.&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Must have a history of severe plaque type psoriasis for at least 6 months, and at&#xD;
             least a 15% affected total body surface area (BSA)&#xD;
&#xD;
          -  Must meet the following clinical laboratory criteria:&#xD;
&#xD;
          -  White Blood Cell Count &gt; or = to 3000/cu mm and &lt; 20,000/cu mm&#xD;
&#xD;
          -  Platelet count &gt; or = to 100,000/microliters&#xD;
&#xD;
          -  Serum creatinine &lt; or = to 1.5 mg/dl&#xD;
&#xD;
          -  Total bilirubin &lt; or = to 2.0 mg/dl&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &lt; or = to 1.5 X ULN&#xD;
&#xD;
          -  Must have a psoriatic plaque &gt; or = to 2.5 cm in diameter (for biopsy)&#xD;
&#xD;
          -  Must be candidate for photo/systemic therapy (a subject is considered a candidate for&#xD;
             photo/systemic therapy if a clinician judges that the subject requires any systemic&#xD;
             therapy (e.g., ultraviolet light B(UVB), Psoralens and long-wave ultraviolet radiation&#xD;
             (PUVA), cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate&#xD;
             mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine)to control&#xD;
             psoriasis whether or not that subject has a history of receiving systemic therapy)&#xD;
&#xD;
          -  Women of child bearing potential (WCBP) must have a negative urine pregnancy test at&#xD;
             Screening (Visit 1). In addition, sexually active WCBP must agree to use two forms of&#xD;
             adequate forms on contraception throughout the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality , or psychiatric illness that&#xD;
             would prevent the subject from signing the informed consent form&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  Current erythrodermic, guttate, or pustular psoriasis&#xD;
&#xD;
          -  Use of medication that is metabolized by the CYP3A4 or CYP2A6 pathways within the 14&#xD;
             days of study medication initiation and/or required use of such medication during&#xD;
             study treatment.&#xD;
&#xD;
          -  Drinking or ingesting grapefruits, grapefruit juice or grapefruit containing products&#xD;
             within 14 days of study medication initiation&#xD;
&#xD;
          -  Use of topical therapy ( topical steroids, topical vitamin A or D analog preparations,&#xD;
             tacrolimus, pimecrolimus, or anthralin) within 14 days of study medications initiation&#xD;
             (Exception: Non-medicated emollients and tar shampoo will be allowed)&#xD;
&#xD;
          -  Use of systemic therapy for psoriasis&#xD;
&#xD;
          -  Use or phototherapy within 28 days of study medication initiation&#xD;
&#xD;
          -  Use Humira or Remicade within 3 months of study medication initiation&#xD;
&#xD;
          -  Use of Enbrel within 56 days of study medication initiation&#xD;
&#xD;
          -  Use of Raptiva within 56 days of study medication initiation&#xD;
&#xD;
          -  Use of Amevive within 6 months of study medication initiation&#xD;
&#xD;
          -  Use of any investigational drug within 30 days of study medication initiation or 5&#xD;
             half lives if known&#xD;
&#xD;
          -  History of clinically significant cardiac, endocrinologic, pulmonary, neurologic,&#xD;
             psychiatric, hepatic, renal, hematologic, immunologic insufficiency disease or other&#xD;
             major diseases&#xD;
&#xD;
          -  Clinically significant abnormality on 12-lead ECG at screening&#xD;
&#xD;
          -  Positive HIV, Hepatitis B or Hepatitis C laboratory result at screening&#xD;
&#xD;
          -  History of active tuberculosis within previous 3 years&#xD;
&#xD;
          -  Clinically significant abnormality on the chest x-ray at screening or on CXR taken&#xD;
             within 6 months of screening&#xD;
&#xD;
          -  History of positive purified protein derivative (PPD) test at screening&#xD;
&#xD;
          -  History of malignancy within previous five years&#xD;
&#xD;
          -  Evidence of skin conditions at the time of screening visit other than psoriasis that&#xD;
             would interfere with evaluations of the effect of study medication on psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008 May;24(5):1529-38. doi: 10.1185/030079908X301866 . Epub 2008 Apr 16.</citation>
    <PMID>18419879</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

